{"id":1299,"date":"2020-06-19T07:10:00","date_gmt":"2020-06-19T07:10:00","guid":{"rendered":"https:\/\/aceoncology.org\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc"},"modified":"2021-03-05T05:14:44","modified_gmt":"2021-03-05T05:14:44","slug":"first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/","title":{"rendered":"First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC"},"content":{"rendered":"\n<p>Around 5% of patients with metastatic colorectal cancer (mCRC) have tumors that are characterized by deficiencies in the mismatch repair system (dMMR), which result in high microsatellite instability (MSI-H). These biomarkers can be identified either by immunohistochemistry (IHC, dMMR), polymerase chain reaction (PCR, MSI) or with next-generation sequencing (NGS). In general, these patients benefit less from conventional chemotherapy and have a poor prognosis. Since MSI-H mCRC is associated with high mutational burden and tumor antigen load, these tumors are highly immunogenic and thus sensitive to immune checkpoint blockade. Several clinical trials have demonstrated high and durable responses with immune checkpoint inhibitors in patients with metastatic dMMR\/MSI-H CRC and non-CRC cancers. These data led to regulatory approvals of <a href=\"https:\/\/medicinainternaelsalvador.com\/wp-content\/uploads\/2017\/11\/first-fda-approval-agnostic-of-cancer-site-%E2%80%94-when-a-biomarker-defines-the-indication.pdf\" rel=\"noreferrer noopener\" target=\"_blank\">pembrolizumab<\/a> for previously treated MSI-H\/dMMR solid tumors, including mCRC, and nivolumab (<a href=\"https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2017.76.9901\" rel=\"noreferrer noopener\" target=\"_blank\">with<\/a> and <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28734759\/\" rel=\"noreferrer noopener\" target=\"_blank\">without<\/a> low dose ipilimumab) for previously treated mCRC with the presence of these biomarkers.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>At the ASCO 2020 virtual plenary session, eagerly awaited results from the randomized, open label, phase III KEYNOTE-177 trial (<a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2020.38.18_suppl.LBA4\" rel=\"noreferrer noopener\" target=\"_blank\">LBA4<\/a>) were presented by <em>Thierry Andr\u00e9<\/em>, <em>MD <\/em>(Sorbonne Universit\u00e9 and H\u00f4pital Saint Antoine, Paris, France). The trial, which enrolled 307 previously untreated patients with MSI-H\/dMMR mCRC, compared the efficacy and safety of first-line pembrolizumab with standard chemotherapy-based therapy. Patients were assigned to receive either first line pembrolizumab or investigator-choice of chemotherapy (modified FOLFOX6 or FOLFIRI) with or without bevacizumab or cetuximab. Patients continued treatment until disease progression (PD), unacceptable toxicity, withdrawal, or completion of 35 cycles of pembrolizumab. Optional crossover to pembrolizumab for patients with verified PD in the chemotherapy arm was permitted. Progression-free survival (PFS) and overall survival (OS) were the dual-primary endpoints for the trial; key secondary endpoints included objective response rate (ORR) and safety. At median follow up of 32 months, treatment with pembrolizumab provided a clinically meaningful and statistically significant improvement in median PFS compared with standard therapy (16.5 versus 8.2 months; hazard ratio (HR) 0.60, <em>P<\/em>=0.0002). Of note, there was the 2.5-fold increase in rate of PFS at 24 months with pembrolizumab treatment (48.3% versus 18.6%).&nbsp;Subgroup analysis indicated consistent benefit with pembrolizumab across all subgroups, although patients with <em>RAS <\/em>mutant mCRC and those with ECOG PS1 appear to benefit less. Confirmed ORR in the pembrolizumab arm was 43.8% versus 33.1% in the chemotherapy arm (<em>P<\/em>=0.027). However, progressive disease was higher in the pembrolizumab arm at 29.4% versus 12.3%, suggesting that around a third of patients may have an intrinsic resistance to anti-PD1 therapy. Median duration of response was not reached with pembrolizumab and was 10.6 months with chemotherapy-based treatment. Among patients with confirmed progression on chemotherapy-based treatment, 36% crossed over to receive pembrolizumab. The study remains blinded for OS, which is planned to be reported at final analysis. The safety profile of pembrolizumab was favorable compared with chemotherapy, and patients experienced a robust decrease in grade 3 or higher treatment-related adverse events (22% versus 66%).<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><em>Dr Andr\u00e9 <\/em>concluded that \u201cno medical treatment has shown such a difference in terms of improvement of progression-free survival in metastatic colorectal cancer\u201d and that \u201cpembrolizumab should be the new standard of care for these patients\u201d. A discussant for KEYNOTE-177, <em>Michael Overman MD <\/em>(The University of Texas MD Anderson Cancer Center, Houston, Texas, USA) agreed that these results are practice changing. He pointed out that it is critical to test all patients with mCRC for MSI-H\/dMMR mutations, and that biomarkers of resistance are needed to identify those patients who may benefit most from first-line pembrolizumab treatment.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>Reference<\/strong><\/p>\n\n\n\n<p>Andr\u00e9 T, et al. <em>J Clin Oncol. <\/em>2020;38 (suppl; abstract LBA4)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Around 5% of patients with metastatic colorectal cancer [&hellip;]<\/p>\n","protected":false},"author":434,"featured_media":741,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[41],"tags":[],"class_list":["post-1299","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-41"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC - ACE Oncology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"Around 5% of patients with metastatic colorectal cancer [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-19T07:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-05T05:14:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/06\/file-1592456570673-Picture-Blog-Post-10_Pembro-inmCRC.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1250\" \/>\n\t<meta property=\"og:image:height\" content=\"834\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pascha Paularin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pascha Paularin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/\"},\"author\":{\"name\":\"Pascha Paularin\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33\"},\"headline\":\"First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC\",\"datePublished\":\"2020-06-19T07:10:00+00:00\",\"dateModified\":\"2021-03-05T05:14:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/\"},\"wordCount\":575,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/06\/file-1592456570673-Picture-Blog-Post-10_Pembro-inmCRC.jpg\",\"articleSection\":[\"\u4f1a\u8bae\u52a8\u6001\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/\",\"name\":\"First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/06\/file-1592456570673-Picture-Blog-Post-10_Pembro-inmCRC.jpg\",\"datePublished\":\"2020-06-19T07:10:00+00:00\",\"dateModified\":\"2021-03-05T05:14:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/06\/file-1592456570673-Picture-Blog-Post-10_Pembro-inmCRC.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/06\/file-1592456570673-Picture-Blog-Post-10_Pembro-inmCRC.jpg\",\"width\":1250,\"height\":834,\"caption\":\"ACE-OncoBlog-10-Pembro-immCRC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33\",\"name\":\"Pascha Paularin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g\",\"caption\":\"Pascha Paularin\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/ppaschaaceoncology-org\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC - ACE Oncology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/","og_locale":"zh_CN","og_type":"article","og_title":"First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC - ACE Oncology","og_description":"Around 5% of patients with metastatic colorectal cancer [&hellip;]","og_url":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/","og_site_name":"ACE Oncology","article_published_time":"2020-06-19T07:10:00+00:00","article_modified_time":"2021-03-05T05:14:44+00:00","og_image":[{"width":1250,"height":834,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/06\/file-1592456570673-Picture-Blog-Post-10_Pembro-inmCRC.jpg","type":"image\/jpeg"}],"author":"Pascha Paularin","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"Pascha Paularin","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"3 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/"},"author":{"name":"Pascha Paularin","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33"},"headline":"First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC","datePublished":"2020-06-19T07:10:00+00:00","dateModified":"2021-03-05T05:14:44+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/"},"wordCount":575,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/06\/file-1592456570673-Picture-Blog-Post-10_Pembro-inmCRC.jpg","articleSection":["\u4f1a\u8bae\u52a8\u6001"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/","url":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/","name":"First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/06\/file-1592456570673-Picture-Blog-Post-10_Pembro-inmCRC.jpg","datePublished":"2020-06-19T07:10:00+00:00","dateModified":"2021-03-05T05:14:44+00:00","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/06\/file-1592456570673-Picture-Blog-Post-10_Pembro-inmCRC.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/06\/file-1592456570673-Picture-Blog-Post-10_Pembro-inmCRC.jpg","width":1250,"height":834,"caption":"ACE-OncoBlog-10-Pembro-immCRC"},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/first-line-pembrolizumab-superior-to-chemotherapy-in-msi-h-mcrc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"First-line Pembrolizumab Superior to Chemotherapy in MSI-H mCRC"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33","name":"Pascha Paularin","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g","caption":"Pascha Paularin"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/ppaschaaceoncology-org\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/1299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/434"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=1299"}],"version-history":[{"count":1,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/1299\/revisions"}],"predecessor-version":[{"id":1300,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/1299\/revisions\/1300"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/741"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=1299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=1299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=1299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}